Skip to content
ChickenStockChickenStock
ResearchFilings

AI English summary of an SEC filing — figures as filed

Abbott Laboratories logoAbbott Laboratories ABT

The company said it notified its named executive officers on November 12, 2024 that the term of the Agreements Regarding Change in Control was extended through December 31, 2026.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Period of report Summary published (UTC)

Key points

AI summary
  1. The company said it notified its named executive officers on November 12, 2024 that the term of the Agreements Regarding Change in Control was extended through December 31, 2026.

  2. The company said that under the existing Agreements, if it gives notice of extension before the Expiration Date (December 31, 2024), the agreement term continues through the second anniversary of the Expiration Date.

  3. The company disclosed in this 8-K under Item 5.02 matters relating to the Agreements Regarding Change in Control with the named executive officers it had previously reported.

  4. The company listed November 12, 2024 as the date of earliest event reported on this Form 8-K, and signed the report on November 15, 2024.

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Abbott Extends Change-in-Control Agreement Term for Executives

The company said it notified its named executive officers on November 12, 2024 that the term of the Agreements Regarding Change in Control was extended through December 31, 2026.

Source · Based on the filing body and exhibits

Existing Agreement Extension Notice Terms and Expiration Date

The company said that under the existing Agreements, if it gives notice of extension before the Expiration Date (December 31, 2024), the agreement term continues through the second anniversary of the Expiration Date.

Source · Based on the filing body and exhibits

Contracts Covered Under Item 5.02 Disclosure

The company disclosed in this 8-K under Item 5.02 matters relating to the Agreements Regarding Change in Control with the named executive officers it had previously reported.

Source · Based on the filing body and exhibits

Report Date and Filing Details

The company listed November 12, 2024 as the date of earliest event reported on this Form 8-K, and signed the report on November 15, 2024.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.